WELLBUTRIN FOR DEPRESSION IN DIABETIC PATIENTS

维布特林 (Wellbutrin) 治疗糖尿病患者抑郁症

• 批准号: 7377217
• 负责人: PATRICK J LUSTMAN
• 金额: $ 2.87万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377217
• 关键词: WELLBUTRIN; DEPRESSION; DIABETIC; PATIENTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diabetes is present in approximately 20,000,000 adults and is a leading cause of morbidity and mortality. Hyperglycemia is the principal cause of the neuropathic, micro- and macrovascular complications of diabetes; accordingly maintenance of normoglycemia has long been the focus of diabetes therapy. However, even with aggressive treatment, glycemic control sufficient to prevent the development of diabetes complications is rarely achieved (1,2). This has intensified the search for modifiable factors that could improve the course of diabetes, and depression management may be one of these factors. Clinical depression, present in approximately 25% of patients with diabetes (type 1 or type 2), is associated with hyperglycemia and with increased risk for complications, particularly macrovascular disease. These observations led to a series of clinical trials to determine whether these associations could me manipulated through depression treatment. These studies indicate that improvement in depression is associated with short-term improvement in glycemic control and insulin resistance; however, the effects of treatment on mood and glucose regulartion are not always parallel nor uniformly prodiabetic. If as happens the depression intervention induces weight gain, a seperate factor promoting hyperglycemia and insulin resistance, the overall effects of depression therapy in the face of diabetes would be devalued. As yet, and agent having concomitant positive and durable effects on depression, glycemic control, and weight is desirable but has not yet been identified.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。糖尿病在大约2000万成年人中存在，是发病率和死亡率的主要原因。高血糖是糖尿病的神经性、微血管和大血管并发症的主要原因；因此，维持正常血糖一直是糖尿病治疗的重点。然而，即使采取积极的治疗，也很少能达到足以防止糖尿病并发症发生的血糖控制（1,2）。这加强了对可以改善糖尿病病程的可改变因素的研究，而抑郁症的管理可能是这些因素之一。约25%的糖尿病患者（1型或2型）出现临床抑郁，与高血糖和并发症（尤其是大血管疾病）风险增加有关。这些观察结果导致了一系列的临床试验，以确定这些关联是否可以通过抑郁症治疗来控制。这些研究表明，抑郁症的改善与血糖控制和胰岛素抵抗的短期改善有关；然而，治疗对情绪和血糖调节的影响并不总是平行的，也不是均匀的。如果抑郁症干预确实导致体重增加，这是促进高血糖和胰岛素抵抗的一个单独因素，那么面对糖尿病，抑郁症治疗的总体效果将被贬低。到目前为止，一种对抑郁、血糖控制和体重同时具有积极和持久作用的药物是可取的，但尚未确定。